Voyager Therapeutics’ management team has deep and relevant manufacturing, discovery, translational, research and development, clinical, regulatory, commercial and financial expertise and a track record of building exceptional life science companies.
Andre Turenne brings to Voyager extensive strategic business development and commercial leadership experience, including nearly 12 years at Genzyme and Sanofi. He most recently served as Sanofi’s senior vice president, global head, business development and licensing, where he was responsible for partnering activities across all of Sanofi’s business units, including Sanofi Pasteur, Sanofi Genzyme, Diabetes-Cardiovascular, General Medicines and Consumer Health, and also served as Chair of the Sanofi Transaction Committee. He previously served as global head of strategy and business development at Genzyme following its acquisition by Sanofi. In addition to his extensive business development transactions and leadership positions, Mr. Turenne has held senior leadership positions at the country level as general manager of Sanofi Genzyme Australia/New Zealand with P&L responsibility for that region and at the global franchise level as head of commercial operations for the Renal and Endocrinology division, which achieved one billion dollars in annual revenues during his time. Mr. Turenne began his career in the industry as a consultant at Kendall Strategies, the consulting arm of Feinstein Kean Healthcare, now part of Ogilvy.
Mr. Turenne holds a B.A. from Kalamazoo College and an M.B.A. from the Tuck School of Business at Dartmouth.
Omar Khwaja brings to Voyager extensive research, translational, and clinical therapeutic development experience in neuroscience, neurogenetics and rare disease in both industry and academic roles. Dr. Khwaja joined Voyager from F. Hoffmann-La Roche AG (Roche), where he most recently served as Global Head of Neuroscience Translational Medicine and Global Head of Rare Diseases. During his seven years at Roche, Dr. Khwaja established an integrated discovery and development rare disease unit with clinical development in neuroscience. Within these groups, Dr. Khwaja led the initiation of Roche’s first clinical programs in gene therapy and delivered into pivotal trials multiple programs across various therapeutic modalities and indications including spinal muscular atrophy (SMA) and Huntington’s disease. Before joining Roche, Dr. Khwaja was Director of the Clinical Neurogenetics Program at Boston Children’s Hospital and on the faculty of Harvard Medical School.
Dr. Khwaja received his M.D. and Ph.D. from the University of Cambridge, Cambridge, UK. He trained in pediatrics and clinical genetics in London, UK and Melbourne, Australia and completed his neurology training at Massachusetts General Hospital and Boston Children’s Hospital, where he was Chief Resident. He is a Member of the Royal Colleges of Physicians of the United Kingdom and a Member of the Royal College of Pediatrics and Child Health.
Allison Dorval is our chief financial officer and serves as Voyager’s principal finance and accounting officer. She has over twenty years of corporate finance and accounting experience, including nine years of life sciences executive finance experience. Prior to Voyager, Ms. Dorval served most recently at Juniper Pharmaceuticals, Inc., and Insulet Corporation, where she led financial planning, reporting and accounting. Previously, Ms. Dorval held corporate finance positions with iBasis, Inc. and Digitas Inc. Ms. Dorval is a certified public accountant and began her career in public accounting at PricewaterhouseCoopers, LLP, where she held positions of increasing responsibility and scope.
Ms. Dorval obtained a Bachelor of Science in Business Administration (accounting concentration) from the University of Vermont.
Allen Nunnally is our chief business officer. His life sciences career spans two decades, focusing on genetically- and genomically-driven technologies and medicines for organizations ranging from early-stage biotechs to Fortune 500 pharma companies. Prior to joining Voyager, Mr. Nunnally served as vice president of corporate and business development and associate general counsel at Foundation Medicine, where he led transactions relating to its biopharmaceutical business in comprehensive genomic profiling, companion diagnostics, and data products and directed the company’s intellectual property strategy. Mr. Nunnally represented Foundation Medicine from its Series B financing through IPO and co-led the R&D collaboration component of a broad strategic transaction through which Roche acquired a majority interest in Foundation Medicine. Mr. Nunnally previously spent 10 years as an attorney at the law firm Wilmer, Cutler, Pickering, Hale and Dorr LLP, where he represented a wide array of leading pharmaceutical and biotechnology clients.
Mr. Nunnally received a B.A. with double majors in biology and law, jurisprudence and social thought from Amherst College and a J.D. from Boston University School of Law with a concentration in intellectual property law.
Robert Hesslein is our general counsel, and his experience includes more than 25 years as an in-house attorney leading and building legal organizations within the biotechnology industry, with specific expertise in domestic and international commercial law, securities and public company reporting, medical data privacy, as well as licensing and business development collaborations. Mr. Hesslein joins Voyager from Foundation Medicine (acquired by Roche in July 2018), where he served as senior vice president, general counsel and chief compliance officer since 2012, responsible for managing corporate governance and all legal matters related to Foundation Medicine’s business including commercial, corporate and business development, compliance, and research and development functions. Prior to Foundation Medicine, Mr. Hesslein was a senior vice president and deputy general counsel at Genzyme Corporation (acquired by Sanofi in April 2011), serving in increasingly senior roles for 16 years, managing the legal support for many of Genzyme’s most significant transactions and establishing and leading Genzyme’s legal support outside of the U.S. Mr. Hesslein began his legal career at Csaplar & Bok (acquired by Gaston & Snow in 1990), a Boston-based law firm where he spent eight years as an associate and four years as a partner.
Mr. Hesslein earned a B.A. from Yale University and received his J.D. from The Cornell Law School.
Michelle Quinn Smith brings over 30 years of experience in human resources to Voyager. Ms. Smith served most recently as Senior Director of Human Resources at Flagship Pioneering as part of Flagship’s Human Resources Leadership team, advising portfolio companies. Before joining Flagship, Michelle was the Global Human Resources Business Leader for Takeda Pharmaceuticals where she was responsible for the creation and execution of HR strategy for therapeutic development in R&D. During her tenure, she led the due diligence and integration of the ARIAD acquisition in 2017. Ms. Smith was the Global Head of Human Resources for Development (R&D) at Sanofi, in addition to holding other positions at Sanofi (and previously Genzyme). Prior to joining the biotech/pharma industry, she held HR positions with Goldman Sachs and Young & Rubicam Advertising in New York City.
Ms. Smith received a B.A. in History from Chestnut Hill College in Philadelphia and currently serves on the Board of Directors for Horse Hugs for Heroes, a therapeutic animal non-profit organization based in Maryland.
Juliana Muscat brings to Voyager Therapeutics over 20 years of extensive experience in Quality ranging from R&D to commercial manufacturing, working both in Europe and the US. Prior to joining Voyager, Dr. Muscat served as the Global Head of Quality for the Novartis Institutes for BioMedical Research (NIBR) covering all early development programs including cell and gene therapy. During her 4 years at NIBR, she was responsible for building and executing the quality strategy for NIBR across research, pre-clinical to early clinical translational medicine across Europe, US and China. Before joining NIBR, Dr. Muscat held various positions in Novartis and Alcon both in Europe and the US, leading organizations in Pharmaceutical & Medical Device development, managing various aspects of Engineering and Quality Assurance. Dr. Muscat has also spent time in academia in Malta and the UK as a visiting Scientist.
Dr. Muscat holds a B.A. in Mechanical Engineering and a Ph.D. in Materials Science which she obtained from the University of Malta, Europe.
Robin Swartz brings more than 20 years of experience across the industry; most recently, as Vice President, Patient and Product Services for Rare Diseases at Genzyme. She was responsible for the U.S. strategy and implementation of patient support and education, customer service and commercial operations for seven brands and two launch programs. During her time at Sanofi Genzyme, Robin also held leadership positions as Vice President, Head of Global and US Business Operations, Chief of Staff to the Executive Vice President, and Senior Director, Finance. She served on the Sanofi Aventis Board of Directors, providing oversight to the US compliance program and was a member of the Executive Community Relations Committee.
Ms. Swartz received a B.A. in Political Science from Kenyon College.